Biocon Limited

NSE BIOCON.NS

Biocon Limited EBIT for the year ending March 31, 2024: USD 309.77 M

Biocon Limited EBIT is USD 309.77 M for the year ending March 31, 2024, a 71.67% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.
  • Biocon Limited EBIT for the year ending March 31, 2023 was USD 180.45 M, a 8.95% change year over year.
  • Biocon Limited EBIT for the year ending March 31, 2022 was USD 165.63 M, a 0.66% change year over year.
  • Biocon Limited EBIT for the year ending March 31, 2021 was USD 164.54 M, a -3.11% change year over year.
  • Biocon Limited EBIT for the year ending March 31, 2020 was USD 169.83 M, a -8.12% change year over year.
Key data
Date EBIT EBITDA Net Income EPS (Diluted)
Market news
NSE: BIOCON.NS

Biocon Limited

CEO Mr. Siddharth Mittal BCom, CA, CPA
IPO Date April 7, 2004
Location India
Headquarters 20th KM, Hosur Road
Employees 16,315
Sector Health Care
Industries
Pharmaceuticals Biotechnology
Description

Biocon Limited, a biopharmaceutical company, manufactures pharmaceuticals, and medicinal chemical and botanical products. The company operates through Generics, Novel Biologics, Biosimilars, and Research Services segments. It focuses in the areas of diabetes, oncology, immunology, ophthalmology, and bone health diseases. In addition, It is involved in the integrated discovery, development, and manufacturing services for small and large molecules. The company serves customers in approximately 120 countries. Biocon Limited was founded in 1978 and is headquartered in Bengaluru, India.

StockViz Staff

January 15, 2025

Any question? Send us an email